Literature DB >> 16932725

Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis.

Dominique Monnet1, Laurence Moachon, Maxime Dougados, Antoine P Brézin.   

Abstract

BACKGROUND: A 36-year-old male presented with bilateral, anterior, chronic uveitis, with cystoid macular edema. Decimal visual acuity was 0.25 in the right eye and 0.20 in the left eye. Ankylosing spondylitis had been diagnosed 13 years previously, with peripheral and axial involvement. He had no history of extra-articular manifestations of ankylosing spondylitis before this uveitis attack. Treatment with the anti-tumor necrosis factor agent etanercept was initiated 5 months before the attack of uveitis. INVESTIGATIONS: Slit-lamp biomicroscopy, laser-flare photometry, optical coherence tomography, chest radiography, angiotensin-converting-enzyme test, mycobacterial culture from gastric lavage, serology tests for syphilis, brucellosis, toxoplasmosis, toxocarosis, antinuclear antibodies, rheumatoid factor, antineutrophil cytoplasmic antibodies, antimyeloperoxydase antibodies and antiproteinase 3 antibodies. DIAGNOSIS: Atypically severe HLA-B27-positive uveitis, in a patient with ankylosing spondylitis treated with etanercept. MANAGEMENT: Intensive topical corticosteroid and cycloplegic treatment, subtenon triamcinolone acetonide injection, switch in treatment from etanercept to infliximab followed by discontinuation of tumor necrosis factor inhibitors, intravenous pulses of methylprednisolone followed by oral corticosteroids, and intravenous cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16932725     DOI: 10.1038/ncprheum0225

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN: 1745-8382


  3 in total

1.  [Differential diagnosis of anterior uveitis].

Authors:  S Thurau; U Pleyer
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

2.  Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.

Authors:  M Rudwaleit; E Rødevand; P Holck; J Vanhoof; M Kron; S Kary; H Kupper
Journal:  Ann Rheum Dis       Date:  2008-07-28       Impact factor: 19.103

3.  Drug-induced uveitis.

Authors:  Nikolas Js London; Sunir J Garg; Ramana S Moorthy; Emmett T Cunningham
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-03-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.